A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
This phase 3 randomized study evaluates the efficacy and safety of high-dose vitamin C in combination with FOLFOX ± bevacizumab in patients with unresectable, untreated metastatic colorectal cancer (CRC). The results suggest that the addition of vitamin C to standard chemotherapy may improve clinical outcomes by enhancing treatment response. However,
June 26, 2025
No Comments